Your browser doesn't support javascript.
loading
Hormônio do crescimento na otimizaçäo do tratamento da insuficiência cardíaca refratária / Growth hormone for optimization of refractory heart failure treatment
Bocchi, Edimar Alcides; Massuda, Zyun; Guimaräes, Guilherme; Carrara, Dirceu; Bellotti, Giovanni; Macelin, Amilcar; Rodrigues Sobrinho, Carlos Roberto Martins; Ramires, José Franchini.
  • Bocchi, Edimar Alcides; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
  • Massuda, Zyun; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
  • Guimaräes, Guilherme; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
  • Carrara, Dirceu; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
  • Bellotti, Giovanni; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
  • Macelin, Amilcar; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
  • Rodrigues Sobrinho, Carlos Roberto Martins; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
  • Ramires, José Franchini; Universidade de Säo Paulo. Faculdade de Medicina. Instituto do Coraçäo.
Arq. bras. cardiol ; 73(4): 391-8, out. 1999. tab
Article in Portuguese, English | LILACS | ID: lil-255036
ABSTRACT
It has been reported that growth hormone may benefit selected patients with congestive heart failure. A 63-year-old man with refractory congestive heart failure waiting for heart transplantation, depending on intravenous drugs (dobutamine) and presenting with progressive worsening of the clinical status and cachexia, despite standard treatment, received growth hormone replacement (8 units per day) for optimization of congestive heart failure management. Increase in both serum growth hormone levels (from 0.3 to 0.8 mg/l) and serum IGF-1 levels (from 130 to 300ng/ml) was noted, in association with clinical status improvement, better optimization of heart failure treatment and discontinuation of dobutamine infusion. Left ventricular ejection fraction (by MUGA) increased from 13 percent to 18 percent and to 28 percent later, in association with reduction of pulmonary pressures and increase in exercise capacity (rise in peak VO2to 13.4 and to 16.2ml/kg/min later). The patient was"de-listed" for heart transplantation. Growth hormone may benefit selected patients with refractory heart failure
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Human Growth Hormone / Heart Failure Type of study: Etiology study Limits: Humans / Male Language: English / Portuguese Journal: Arq. bras. cardiol Journal subject: Cardiology Year: 1999 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Human Growth Hormone / Heart Failure Type of study: Etiology study Limits: Humans / Male Language: English / Portuguese Journal: Arq. bras. cardiol Journal subject: Cardiology Year: 1999 Type: Article